Yonhap Infomax News2d ago
Celltrion's Zymfentra prescriptions in the US reached record highs in January 2026, surging 213% year-on-year, with shipments to distributors increasing 3.5-fold, driven by the company's comprehensive 3P marketing strategy targeting providers, payers, and patients across multiple channels.
#YonhapInfomax #Celltrion #Zymfentra #Infliximab #PrescriptionGrowth #USPharmaceuticalMarket #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=110507
Yonhap Infomax NewsJan 28
Celltrion reported that its infliximab SC drug Zymfentra achieved record-high weekly prescriptions in the US, up 27% month-on-month and 352% year-on-year, driven by intensified marketing efforts.
#YonhapInfomax #Celltrion #Zymfentra #PrescriptionVolume #USMarket #MarketingStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102451
Celltrion Says Zymfentra Sets All-Time Weekly Prescription Record in US

Celltrion reported that its infliximab SC drug Zymfentra achieved record-high weekly prescriptions in the US, up 27% month-on-month and 352% year-on-year, driven by intensified marketing efforts.

Yonhap Infomax
Yonhap Infomax NewsJan 12
Celltrion projects record Q4 earnings with a 140% surge in operating profit, but repeated guidance cuts and missed targets raise questions about market confidence.
#YonhapInfomax #Celltrion #OperatingProfit #RevenueGuidance #Zymfentra #MarketConfidence #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99385
Celltrion Forecasts Record Q4 Earnings—Can It Restore Market Confidence

Celltrion projects record Q4 earnings with a 140% surge in operating profit, but repeated guidance cuts and missed targets raise questions about market confidence.

Yonhap Infomax